BUZZ-Decoy Therapeutics rises as Gates Foundation backs antiviral drug access

Reuters

Yesterday

BUZZ-Decoy <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises as Gates Foundation backs antiviral drug access

** Shares of drug developer Decoy Therapeutics DCOY.O rise 6.99% to $0.872 premarket

** Co says it has reached agreement with Gates Foundation to develop manufacturing platform for antiviral drugs

** Platform aims to make antivirals widely available in low- and middle-income countries, co says

** Technology called IMP3ACT enables rapid design and production of drugs for viruses such as flu and people with weakened immune systems, co adds

** Co plans to validate platform with experimental nasal spray to prevent coronavirus infections in immunocompromised people

** Lead antiviral candidate expected to be submitted to U.S. regulators within a year, DCOY says

** As of last close, stock down ~97% over past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2603024684"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603024684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603024684?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603024684","market":"fut","top_or_hot":-1,"title":"BUZZ-Decoy Therapeutics rises as Gates Foundation backs antiviral drug access","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Decoy <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rises as Gates Foundation backs antiviral drug access</title></head><body><p>** Shares of drug developer Decoy Therapeutics <span>DCOY.O</span> rise 6.99% to $0.872 premarket </p><p>** Co says it has reached agreement with Gates Foundation to develop manufacturing platform for antiviral drugs</p><p>** Platform aims to make antivirals widely available in low- and middle-income countries, co says</p><p>** Technology called IMP3ACT enables rapid design and production of drugs for viruses such as flu and people with weakened immune systems, co adds</p><p>** Co plans to validate platform with experimental nasal spray to prevent coronavirus infections in immunocompromised people</p><p>** Lead antiviral candidate expected to be submitted to U.S. regulators within a year, DCOY says</p><p>** As of last close, stock down ~97% over past year</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Decoy Therapeutics rises as Gates Foundation backs antiviral drug access</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Decoy Therapeutics rises as Gates Foundation backs antiviral drug access\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 21:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Decoy <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rises as Gates Foundation backs antiviral drug access</title></head><body><p>** Shares of drug developer Decoy Therapeutics <span>DCOY.O</span> rise 6.99% to $0.872 premarket </p><p>** Co says it has reached agreement with Gates Foundation to develop manufacturing platform for antiviral drugs</p><p>** Platform aims to make antivirals widely available in low- and middle-income countries, co says</p><p>** Technology called IMP3ACT enables rapid design and production of drugs for viruses such as flu and people with weakened immune systems, co adds</p><p>** Co plans to validate platform with experimental nasal spray to prevent coronavirus infections in immunocompromised people</p><p>** Lead antiviral candidate expected to be submitted to U.S. regulators within a year, DCOY says</p><p>** As of last close, stock down ~97% over past year</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nL4N3YE17R:1","article_id":"2603024684","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603024684","pubTimestamp":1768310693,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Decoy Therapeutics rises as Gates Foundation backs antiviral drug access** Shares of drug developer Decoy Therapeutics DCOY.O rise 6.99% to $0.872 premarket ** Co says it has reached agreement with Gates Foundation to develop manufacturing platform for antiviral drugs** Platform aims to make antivirals widely available in low- and middle-income countries, co says** Technology called IMP3ACT enables rapid design and production of drugs for viruses such as flu and people with weakened immune systems, co adds** Co plans to validate platform with experimental nasal spray to prevent coronavirus infections in immunocompromised people** Lead antiviral candidate expected to be submitted to U.S. regulators within a year, DCOY says** As of last close, stock down ~97% over past year  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DCOY":"Decoy Therapeutics Inc"},"translate_title":"盖茨基金会支持抗病毒药物获取，BUZZ-Decoy Therapeutics崛起","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCOY":0.9},"content_text":"BUZZ-Decoy Therapeutics rises as Gates Foundation backs antiviral drug access** Shares of drug developer Decoy Therapeutics DCOY.O rise 6.99% to $0.872 premarket ** Co says it has reached agreement with Gates Foundation to develop manufacturing platform for antiviral drugs** Platform aims to make antivirals widely available in low- and middle-income countries, co says** Technology called IMP3ACT enables rapid design and production of drugs for viruses such as flu and people with weakened immune systems, co adds** Co plans to validate platform with experimental nasal spray to prevent coronavirus infections in immunocompromised people** Lead antiviral candidate expected to be submitted to U.S. regulators within a year, DCOY says** As of last close, stock down ~97% over past year (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}